The effect of ozagrel sodium on photochemical thrombosis in rat: Therapeutic window and combined therapy with heparin sodium

Life Sciences

Volumn 71, Issue 25, 2002, Pages 2983-2994

  Arii, Kazumasa ^a   Igarashi, Hironaka ^a   Arii, Takako ^a   Katayama, Yasuo ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Cerebral artery thrombosis; Cerebral infarction; Heparin; Ozagrel; Rat; Rose bengal

Indexed keywords

DRUG VEHICLE; HEPARIN; OZAGREL; PHOTOSENSITIZING AGENT; ROSE BENGAL; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN EDEMA; BRAIN INFARCTION; BRAIN RADIATION; CONTROLLED STUDY; DISEASE DURATION; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; HEPARINIZATION; LIGHT; MALE; MONOTHERAPY; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; RAT; THROMBOSIS; TREATMENT OUTCOME;

ANIMALS; CEREBRAL ARTERIES; CEREBRAL INFARCTION; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; HEPARIN; IMAGE PROCESSING, COMPUTER-ASSISTED; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTRACRANIAL THROMBOSIS; LIGHT; MALE; METHACRYLATES; RATS; RATS, SPRAGUE-DAWLEY; THROMBOXANE-A SYNTHASE; TIME FACTORS; TREATMENT OUTCOME;

ANIMALIA;

EID: 0037044707     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(02)02165-3     Document Type: Article

References (44)

1. Hamberg M., Svensson J., Samuelsson B. Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proceedings of the National Academy of Sciences of the United States of America. 72(8):1975;2994-2998.
2. Bunting S., Moncada S., Vane J.R. The effects of prostaglandin endoperoxides and thromboxane A2 on strips of rabbit coeliac artery and certain other smooth muscle preparations. British Journal of Pharmacology. 57(3):1976;462-463.
3. Chen S.T., Hsu C.Y., Hogan E.L., Halushka P.V., Linet O.I., Yatsu F.M. Thromboxane, prostacyclin, and leukotrienes in cerebral ischemia. Neurology. 36(4):1986;466-470.
4. Moncada S., Gryglewski R.J., Bunting S., Vane J.R. An enzyme isolated from arteries transforms prostaglandin endoperoxides to and unstable substance that inhibits platelet aggregation. Nature. 263(5579):1976;663-665.
5. Ujiie A., Hiraku S., Naito J. Pharmacological actions of OKY-046, a specific inhibitor of thromboxane synthetase, with special reference to inhibition of Thromboxane A2 production and acceleration of prostacyclin production. Pharmacometrics. 29(5):1985;659-685.
6. Hiraku S., Taniguchi K., Wakitani K., Omawari N., Kira H., Miyamoto T., Okegawa T., Kawasaki A., Ujiie A. Pharmacological studies on the TXA2 synthetase inhibitor (E)-3-[p-(1H-imidazol-1-Y methyl)phenyl]-2-propenoic acid (OKY-046). Japanese Journal of Pharmacology. 41(3):1986;393-401.
7. Asano T., Sasaki T., Johshita H., Takakura K. Experimental evaluation of the effect of thromboxane A2 synthase inhibitors on ischemic brain injury. Ensho (in Japanese). 4 Supplement:1984;91-94.
8. Oshima T., McCluskey E.R., Honda A. Pharmacological manipulation of canine cyclooxygenase and thromboxane synthetase in vivo: differential renal and platelet recovery rates. Journal of Pharmacology and Experimental Therapeutics. 229(2):1984;598-602.
9. Yamashita T., Kikuchi H., Karasawa J., Ikoda T., Takeuchi S., Minamikawa J., Hashimoto K., Miyamoto T., Ihara I. Effect of the selective thromboxane synthase inhibitor OKY-046 on acute cerebral ischemia with reperfusion. Gendai Iryo (in Japanese). 18:1986;652-654.
10. Sadoshima S., Ooboshi H., Okada Y., Yao H., Ishitsuka T., Fujishima M. Effect of thromboxane synthase inhibitor on cerebral circulation in spontaneously hypertensive rats. European Journal of Pharmacology. 169(1):1989;75-83.
11. Fukushima M., Kubo K., Yoshimura K. Phase I study of OKY-046, a selective thromboxane synthetase inhibitor. Japanese Pharmacology and Therapeutics. 14:1986;277-307.
12. Uyama O., Nagatsuka K., Nakabayashi S., Isaka Y., Yoneda S., Kimura K., Abe H. The effect of a thromboxane synthase inhibitor, OKY-046, on urinary excretion of immunoreactive thromboxane B2 and 6-keto-prostaglandin F1α in patients with ischemic cerebrovascular disease. Stroke. 16(2):1985;241-244.
13. Mitsumori K., Isobe M., Nakagawa T., Sakuragi M., Motomiya M. Effects of OKY-046, thromboxane synthetase inhibitor on cerebral blood flow and neurologic recovery in patients with acute ischemic stroke. Japanese Pharmacology and Therapeutics. 19:1991;2807-2816.
14. Ohtomo E., Kutsuzawa T., Kogure K., Hirai S., Goto F., Terashi A., Tazaki Y., Araki G., Ito E., Sawada T., Fujishima M. Clinical efficacy of a selective thromboxane synthase inhibitor, OKY-046 on acute cerebral thrombosis-Early phase II study by a multicenter open clinical trial-. Rinsho Iyaku (in Japanese). 7:1991;299-320.
15. Imura Y., Kiyota Y., Nagai Y., Nishikawa K., Terashita Z. Beneficial effect of CV-4151 (Isbogrel), a thromboxane A2 synthase inhibitor, in a rat middle cerebral artery thrombosis model. Thrombosis Research. 79(1):1995;95-107.
16. Iijima T., Sawa H., Shiokawa Y., Saito I., Ishii H., Nakamura Z., Sankawa H. Thromboxane synthetase inhibitor ameliorates delayed neuronal death in the CA1 subfield of the hippocampus after transient global ischemia in gerbils. Journal of Neurosurgical Anesthesiology. 8(3):1996;237-242.
17. Ichikawa K., Tazawa S., Hamano S., Kojima M., Hiraku S. Effect of Ozagrel on locomotor and motor coordination after transient cerebral ischemia in experimental animal models. Pharmacology. 59(5):1999;257-265.
18. Watson B.D., Dietrich W.D., Busto R., Wachtel M.S., Ginsberg M.D. Induction of reproducible brain infarct by photochemically initiated thrombosis. Annals of Neurology. 17(5):1985;497-504.
19. Chaves C.J., Caplan L.R. Heparin and oral anticoagulants in the treatment of brain ischemia. Journal of the Neurological Sciences. 173(1):2000;3-9.
20. Tollefsen D.M., Majerus D.W., Blank M.K. Heparin cofactor II: purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. Journal of Biological Chemistry. 257(5):1982;2162-2169.
21. Lane D.A., Denton J., Flynn A.M., Thunberg L., Lindahl U. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor4. Biochemical Journal. 218(3):1984;725-732.
22. Oosta G.M., Gardner W.T., Beeler D.L., Rosenberg R.D. Multiple functional domains of the heparin molecule. Proceedings of the National Academy of Sciences of the United States of America. 78(2):1981;829-833.
23. Nesheim M.E. A simple rate law that describes the kinetics of the heparin-catalyzed reaction between antithrombinIII and thrombin. Journal of Biological Chemistry. 258(23):1983;14708-14717.
24. Ofosu F.A., Sie P., Modi G.J., Fernandez F., Buchanan M.R., Blajchman M.A., Boneu B., Hirsh J. The inhibition of thrombin-dependent feedback reactions is critical to the expression of anticoagulant effects of heparin. Biochemical Journal. 243(2):1987;579-588.
25. Ofosu F.A., Hirsh J., Esmon C.T., Modi G.J., Smith L.M., Anvari N., Buchanan M.R., Fenton J.W. 2nd, Blajchman M.A. Unfractionated heparin inhibits thrombin-catalyzed amplification reactions of coagulation more efficiently than those catalyzed by factor Xa. Biochemical Journal. 257(1):1989;143-150.
26. Beguin S., Lindhout T., Hemker H.C. The mode of action of heparin in plasma. Thrombosis and Haemostasis. 60(3):1988;457-462.
27. Kawano K., Ikeda Y., Kondo K., Umemura K. Superiority of platelet integrin GPIIb-IIIa receptor antagonist over aspirin in preventing cyclic flow reductions in the guinea pig middle cerebral artery. European Journal of Pharmacology. 374(3):1999;377-385.
28. International Stroke Trial Collaborative Group The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet. 349(9065):1997;1569-1581.
29. Suga M., Sachi S., Sugimoto J., Nakashima M. Comparison of efficacy of the selective antithrombotic agent, argatroban, and thromboxane A2 synthase inhibitor, ozagrel sodium, on photochemically induced middle cerebral artery thrombosis. Journal of New Remedies and Clinics. 45:1996;1925-1933.
30. Dietrich W.D., Watson B.D., Busto R., Ginsberg M.D., Bethea J.R. Photochemically induced cerebral infarction: I. Early microvascular alterations. Acta Neuropathologica (Berlin). 72(4):1987;315-325.
31. Umemura K., Wada K., Uematsu T., Nakashima M. Evaluation of the combination of a tissue-type plasminogen activator, SUN9216, and a thromboxane A2 receptor antagonist, Vapiprost, in a rat middle cerebral artery thrombosis model. Stroke. 24(7):1993;1077-1082.
32. Chen S.T., Hsu C.Y., Hogan E.L., Maricq H., Balentine J.D. A model of focal ischemic stroke in the rat: Reproducible extensive cortical infarction. Stroke. 17(4):1986;738-743.
33. Crowther MA, Ginsberg J. Hemostasis and antithrombotic therapy. In: Barnett HJM, Mohr JP, Stein BM, Yatsu FM, editors. Stroke. 3rd. ed. New York: Churchill Livingstone, p1031
34. O'Sullivan E.F., Hirsh J., McCarthy R.A., de Gruchy G.C. Heparin in the treatment of thrombo-embolic disease: administration, control and results. The Medical Journal of Australia. 2(4):1968;153-159.
35. Li P.A., He Q.P., Siddiqui M.M., Shuaib A. Post treatment with low molecular weight heparin reduces brain edema and infarct volume in rats subjected to thrombotic middle cerebral artery occlusion. Brain Research. 801(1-2):1998;220-223.
36. Yanaka K., Spellman S.R., McCarthy J.B., Low W.C., Camarata P.J. Reduction of brain injury using heparin to inhibit leukocyte accumulation in a rat model of transient focal cerebral ischemia. II. Dose-response effect and the therapeutic window. Journal of Neurosurgery. 85(6):1996;1108-1112.
37. Kawai N., Nakamura T., Okauchi M., Nagao S. Effect of heparin and N-acethylheparin on reperfusion injury in focal cerebral ischemia with reperfusion. Japanese Journal of Stroke. 21:1999;149.
38. Xiao Z., Théroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation. 97(3):1998;251-256.
39. Dietrich W.D., Prado R., Watson B.D. Photochemically stimulated blood-borne factors induce blood-brain barrier alterations in rats. Stroke. 19(7):1988;857-862.
40. Wester P., Dietrich W.D., Prado R., Watson B.D., Globus M.Y.-T. Serotonin release into plasma during common carotid artery thrombosis in rats. Stroke. 23(6):1992;870-875.
41. Lavine S.D., Hofman F.M., Zlokovic B.V. Circulating antibody against tumor necrosis factor-alpha protects rat brain from reperfusion injury. Journal of Cerebral Blood Flow and Metabolism. 18(1):1997;52-58.
42. Vogel J., Hermes H., Kuschinsky W. Evolution of microcirculatory disturbances after permanent middle cerebral artery occlusion in rats. Journal of Cerebral Blood Flow and Metabolism. 19(12):1999;1322-1328.
43. Lee V.M., Burdett N.G., Carpenter T.A., Hall L.D., Pambakin P.S., Patel S., Wood N.I., Jamea M.F. Evolution of photochemically induced focal cerebral ischemia in the rat: magnetic resonance imaging and histology. Stroke. 27(11):1996;2110-2118.
44. Dietrich W.D., Ginsberg M.D., Busto R., Watson B.D. Photochemically induced cortical infarction in the rat. 1. Time course of hemodynamic consequences. Journal of Cerebral Blood Flow and Metabolism. 6(2):1986;184-194.